Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Occurrence and Prognostic Relevance of CD30 Expression in Post-transplant Lymphoproliferative Disorders

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Incidence and impact of parvovirus B19 infection in seronegative solid organ transplant recipients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Parkinson patients have a presynaptic serotonergic deficit: A dynamic deep brain stimulation PET study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Abstract Posttransplant lymphoproliferative disorders (PTLDs) are potentially fatal, often Epstein-Barr virus (EBV)-driven neoplasias developing in immunocompromised hosts. Initial treatment usually consists of a reduction in immunosuppressive therapy and/or rituximab with or without chemotherapy. However, patients who relapse do poorly and new treatment options are warranted. With the introduction of the immunoconjugate brentuximab vedotin, the CD30 antigen has become an effectively targetable molecule. Therefore, we investigated the frequency and level of CD30 expression in PTLDs. We identified 108 PTLD patients diagnosed during 1994-2011, of which 62 had adequate paraffin embedded tissue for tissue microarray construction. Immunohistochemical expression of CD30 was consistently detected in all types of PTLD (overall 85.25%), including the monomorphic subtypes, and was correlated to a more favorable outcome. For diffuse large B-cell lymphoma (DLBCL)-type PTLD this was regardless of EBV-status, and remained significant in multivariate analyses. Cell-of-origin had no independent prognostic value in our series of DLBCL PTLD
Original languageEnglish
JournalLeukemia and Lymphoma
Volume56
Issue number6
Pages (from-to)1677-85
Number of pages9
ISSN1042-8194
DOIs
Publication statusPublished - 2015

    Research areas

  • therapy

ID: 44823719